Ronald Pauli

Mr. Pauli brings significant financial and business development experience to BioQ Pharma. He previously served as Chief Financial Officer of Sagent Pharmaceuticals (SGNT) during its initial public offering, which raised $92 million and was one of 2011’s most successful healthcare IPOs. He was intimately involved in Sagent’s negotiations, due diligence, and documentation of over 50 international development, supply, and marketing agreements, including a joint venture that constructed a FDA-compliant sterile injectable manufacturing facility in Chengdu, China. Previously, Mr. Pauli held senior positions at a number of biopharmaceutical companies, including NeoPharm, Inc. and Abraxis BioScience, Inc. (formerly American Pharmaceutical Partners, Inc.). Mr. Pauli currently serves as a member of the board of directors of Horizon Pharmaceuticals (NASDAQ: HZNP) and is the audit committee chair. He earned a BA in Accounting from Michigan State and a Master of Science in Finance with distinction from Walsh College.